A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC)

PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease representing 12-13% of total lung cancers, with median survival <2 years. No targeted therapies have proven effective in SCLC. While most patients respond initially to cytotoxic chemotherapies, resistance rapidly emerges, respo...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Gaponova, Anna V., Nikonova, Anna S., Deneka, Alexander, Kopp, Meghan C., Kudinov, Alexander E., Skobeleva, Natalia, Khazak, Vladimir, Ogawa, Luisa S., Cai, Kathy Q., Duncan, Kelly E., Duncan, James S., Egleston, Brian L., Proia, David A., Boumber, Yanis, Golemis, Erica A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5065742/
https://ncbi.nlm.nih.gov/pubmed/27267850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-3068
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk